Potentiation of the in vitro activity of the multi-targeted antifolate MTA (LY231514) by dipyridamole

被引：0
|
作者：
Smith, PG [1 ]
Newell, DR [1 ]
Barnes, MJ [1 ]
Calvert, AH [1 ]
Curtin, NJ [1 ]
机构：
[1] Univ Newcastle Upon Tyne, Canc Res Unit, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
来源：
ANNALS OF ONCOLOGY | 1998年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
588
引用
收藏
页码：154 / 154
页数：1
相关论文
共 50 条
  • [1] A phase II trial of multi-targeted antifolate (MTA) (LY231514) in patients with unresectable pancreatic cancer
    Miller, KD
    Loehrer, PJ
    Picus, J
    Blanke, C
    John, W
    Clark, J
    Schulman, LN
    Burris, H
    Thornton, D
    ANNALS OF ONCOLOGY, 1998, 9 : 46 - 46
  • [2] Quality of life assessments of patients with pancreatic cancer receiving MTA (LY231514, a multi-targeted antifolate)
    Liepa, AM
    Picus, J
    Blanke, C
    John, W
    Clark, J
    Schulman, L
    Burris, A
    Thornton, D
    Loehrer, PJ
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : OP19 - OP19
  • [3] Activity of the multi-targeted antifolate MTA (LY231514) in advanced non-small cell lung cancer (NSCLC)
    Clarke, S
    Millward, M
    Findlay, M
    Ackland, S
    Hosie, D
    Abratt, R
    Goedhals, L
    ANNALS OF ONCOLOGY, 1998, 9 : 86 - 87
  • [4] Dipyridamole potentiates the in vitro activity of MTA (LY231514) by inhibition of thymidine transport
    P G Smith
    E Marshman
    D R Newell
    N J Curtin
    British Journal of Cancer, 2000, 82 : 924 - 930
  • [5] Dipyridamole potentiates the in vitro activity of MTA (LY231514) by inhibition of thymidine transport
    Smith, PG
    Marshman, E
    Newell, DR
    Curtin, NJ
    BRITISH JOURNAL OF CANCER, 2000, 82 (04) : 924 - 930
  • [6] Effects of MTA (multi-targeted antifolate, LY231514) on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells
    Chen, VJ
    Bewley, JR
    Andis, SL
    Schultz, RM
    Shih, C
    Mendelsohn, LG
    Seitz, DE
    Tonkinson, JL
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 803 - 803
  • [7] A multicentre phase II trial of the multi-targeted antifolate MTA (LY231514) in chemonaive patients with metastatic renal cell carcinoma
    Sauter, T
    Boucsein, G
    Thoedtmann, R
    Miller, K
    Ohnmacht, U
    Blatter, J
    Hanauske, AR
    ANNALS OF ONCOLOGY, 1998, 9 : 61 - 61
  • [8] A phase I study of MTA (multi-targeted antifolate, LY231514) plus cisplatin (CIS) in patients with advanced solid tumours
    Thoedtmann, R
    Kemmerich, M
    Depenbrock, H
    Blatter, J
    Ohnmacht, U
    Rastetter, J
    Hanauske, AR
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 1116 - 1116
  • [9] Significant activity of the multi-targeted antifolate MTA (LY231514) in advanced transitional cell carcinoma (TCC) of the bladder: Results of a phase II trial
    Paz-Ares, L
    Tabemero, J
    Moyano, A
    Rifa, J
    Alonso, S
    Marcuello, E
    Gonzalez, A
    Castellano, D
    Hemandez, S
    Cortes-Funes, H
    ANNALS OF ONCOLOGY, 1998, 9 : 61 - 61
  • [10] Significant activity of the multi-targeted antifolate MTA (LY231514) in advanced transitional cell carcinoma (TCC) of the bladder:: Results of a phase II trial.
    Paz-Ares, J
    Tabernero, A
    Moyano, A
    Rifa, J
    Alonso, S
    Marcuello, E
    Gonzalez, A
    Castellano, D
    Cortés-Funes, H
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S81 - S81
12345